ENSA

Across TCGA pan-cancer cohorts, ENSA mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated ENSA data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ENSA mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ENSA expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where ENSA mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.530	0.223	.001	45	view →
CCRCC	DFS	Tertile	III,IV	1.000	0.756	.005	34	view →
LUAD	OS	Median	All	1.000	0.746	.002	12	view →
COAD	DFS	Median	IV	1.000	0.605	.043	6	view →
OV	DFS	Tertile	All	1.000	0.802	.044	4	view →
UCEC	DFS	Quartile	II,III,IV	1.000	0.550	.025	4	view →
HNSC	DFS	Median	IV	0.328	0.889	.014	4	view →
LSCC	OS	Quartile	All	1.000	0.905	.025	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

ENSA–PDAC (DFS)

Open the PDAC breakdown →